Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005.
Tyndall A,
Walker UA,
Cope A,
Dazzi F,
De Bari C,
Fibbe W,
Guiducci S,
Jones S,
Jorgensen C,
Le Blanc K,
Luyten F,
McGonagle D,
Martin I,
Bocelli-Tyndall C,
Pennesi G,
Pistoia V,
Pitzalis C,
Uccelli A,
Wulffraat N,
Feldmann M.
Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH-4012, Switzerland. alan.tyndall@fps-basel.ch
Multipotent mesenchymal stromal cells isolated from bone marrow and other sites are currently being studied to determine their potential role in the pathogenesis and/or management of autoimmune diseases. In vitro studies have shown that they exhibit a dose-dependent antiproliferative effect on T and B lymphocytes, dendritic cells, natural killer cells and various B cell tumour lines--an effect that is both cell contact and soluble factor dependent. Animal models of autoimmune disease treated with multipotent mesenchymal stromal cells have mostly exhibited a positive clinical response, as have a limited number of patients suffering from acute graft versus host disease. This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts.
PMID: 17284303 [PubMed - indexed for MEDLINE]
PMCID: PMC1860056